Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term phase-ii trial. Found 32 abstracts

no pagination
Psyrri A, Yu ZW, Weinberger PM, Sasaki C, Haffty B, Camp R, Rimm D, Burtness BA. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clinical Cancer Research. 2005 Aug 15;11(16):5856-62.
Swaby RF, Bhalla KN. Importance of rational pre-clinical development - Gemcitabine comes of age. CANCER BIOLOGY & THERAPY. 2005 Aug;4(8):872-3.
Rowinsky EK, Schwartz GH, Gollob JA, Thompson JA, Vogelzang NJ, Figlin R, Bukowski R, Haas N, Lockbaum P, Li YP, Arends R, Foon KA, Schwab G, Dutcher J. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. Journal of Clinical Oncology. 2004 Aug;22(15):3003-15.
Damjanov N, Meropol NJ. Oral therapy for colorectal cancer: How to choose. Oncology-New York. 2000 Jun;14(6):799-807.
Glisson B, Scott C, Komaki R, Movsas B, Wagner H. Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: Results of radiation therapy oncology group trial 93-12. Journal of Clinical Oncology. 2000 Aug;18(16):2990-5.
Bunn PA, Vokes EE, Langer CJ, Schiller JH. An update on North American randomized studies in non-small cell lung cancer. Seminars in Oncology. 1998 Aug;25(4):2-10.
Witte RS, Ryan LM, Schutt AJ, Carbone PP, Engstrom PF. PALA versus streptozotocin, doxorubicin, and MeCCNU in the treatment of patients with advanced pancreatic carcinoma. Investigational New Drugs. 1998 Jan;16(4):315-8.
Young RC. Metastatic renal-cell carcinoma: What causes occasional dramatic regressions?. New England Journal of Medicine. 1998 Apr 30;338(18):1305-6.
Maloney DG, GrilloLopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997 Sep 15;90(6):2188-95.
Ozols RF. Future directions in the chemotherapy of ovarian cancer. Seminars in Oncology. 1997 Oct;24(5):86-90.
Lee JS, Scott C, Komaki R, Fossella FV, Dundas GS, McDonald S, Byhardt RW, Curran WJ. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation therapy oncology group protocol 91-06. Journal of Clinical Oncology. 1996 Apr;14(4):1055-64.
Ozols RF. Ovarian-Cancer .2. Treatment. Current Problems in Cancer. 1992 Mar;16(2):U63-&.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term phase-ii trial

Last updated on Wednesday, February 05, 2020